Related Experiment Videos
Thorotrast-induced ruptured hepatic angiosarcoma
M V Azodo1, O H Gutierrez, T Greer
1Department of Radiology, University of Rochester School of Medicine and Dentistry, Strong Memorial Hospital, New York.
Abdominal Imaging
|January 1, 1993
Summary
Thorotrast, a historical contrast agent, can cause rare liver cancer (hepatic angiosarcoma) decades after exposure. This case highlights the long-term risks and diagnostic challenges associated with Thorotrast-induced tumors.
Area of Science:
- Radiology and Oncology
- Toxicology and Carcinogenesis
Background:
- Thorotrast, a thorium dioxide-based contrast medium, was widely used historically.
- Its use is now discontinued due to long-term risks, including malignancy.
- Thorotrast-induced angiosarcoma is a rare but significant oncological concern.
Observation:
- The case involves a patient who received Thorotrast for diagnostic imaging.
- A hepatic angiosarcoma developed 37 years post-administration.
- Characteristic opacification of the liver, spleen, and lymph nodes was noted.
Findings:
- The study details a case of delayed-onset hepatic angiosarcoma.
- A 37-year latency period between Thorotrast exposure and tumor diagnosis is documented.
- The findings underscore the prolonged carcinogenic potential of Thorotrast.
Implications:
- This case emphasizes the importance of long-term patient follow-up after Thorotrast exposure.
- It highlights the diagnostic challenges posed by delayed-onset, rare cancers.
- Understanding Thorotrast's oncogenesis is crucial for managing historical exposures and preventing future risks.